Esperion Therapeutics (NASDAQ: ESPR) outlines 2026 expense guidance ranges

Rhea-AI Filing Summary

Esperion Therapeutics, Inc. reported preliminary 2025 results and shared expense guidance for the fiscal year ending December 31, 2026. Management currently expects 2026 research and development expenses to range from $40 million to $50 million, selling, general and administrative expenses to range from $170 million to $195 million, and total operating expenses to range from $210 million to $245 million. The figures reflect management’s current expectations and were released in connection with the company’s presentation at the Annual J.P. Morgan Healthcare Conference.

Insights

Biopharma equity analyst

Esperion provides 2026 expense ranges, framing expected cost base.

Esperion Therapeutics has outlined its expected cost structure for the year ending December 31, 2026. The company projects research and development expenses of $40 million to $50 million, which gives a sense of planned investment in its pipeline and ongoing studies.

Selling, general and administrative expenses are forecast at $170 million to $195 million, with total operating expenses estimated between $210 million and $245 million. These ranges suggest that commercial and corporate spending will represent the majority of the expense base.

The guidance is explicitly based on management’s current expectations and is linked to preliminary 2025 results shared around the J.P. Morgan Healthcare Conference. Actual outcomes will depend on how closely execution, market conditions and any strategic decisions track these initial projections.

FALSE000143486800014348682026-01-112026-01-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 11, 2026

Esperion Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-35986

26-1870780

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

3891 Ranchero Drive, Suite 150

Ann Arbor, MI

(Address of principal executive offices)

48108

(Zip Code)

Registrant’s telephone number, including area code: (734) 887-3903

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ESPR

NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐

Item 2.02. Results of Operations and Financial Condition.

On January 11, 2026, Esperion Therapeutics, Inc. issued a press release and released its management presentation for the upcoming Annual J.P. Morgan Healthcare Conference announcing preliminary 2025 results and the following financial guidance for the fiscal year ending December 31, 2026, which guidance is based on management’s current expectations for the business: (i) research & development expenses are expected to be in the range of $40 million to $50 million; (ii) selling, general and administrative expenses are expected to be in the range of $170 to $195 million; and (iii) operating expenses are expected to be in the range of $210 million to $245 million. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 2.02 by reference. Selected slides from the Company’s presentation are attached as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

The information in this Current Report on Form 8-K, Exhibit 99.1 and Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about the Company’s expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “continue,” and similar expressions, or the negative of these terms. These forward-looking statements include statements about the Company’s expected full year expenses and financial performance. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward- looking statements are qualified in their entirety by reference to the factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company’s other reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.						Description
99.1						Press Release dated January 11, 2026
99.2						Slides from Presentation of the Company, dated January 11, 2026.
104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026			Esperion Therapeutics, Inc.
			By:			/s/ Sheldon L. Koenig
						Sheldon L. Koenig
						President and Chief Executive Officer

FAQ

What 2026 expense guidance did Esperion Therapeutics (ESPR) provide?

For the fiscal year ending December 31, 2026, Esperion expects research and development expenses of $40 million to $50 million, selling, general and administrative expenses of $170 million to $195 million, and total operating expenses of $210 million to $245 million.

What triggered this Esperion Therapeutics (ESPR) Form 8-K filing?

The filing was made after Esperion issued a press release and management presentation for the Annual J.P. Morgan Healthcare Conference, where it announced preliminary 2025 results and 2026 expense guidance.

How much is Esperion guiding for 2026 R&D spending?

Esperion is guiding for 2026 research and development expenses in the range of $40 million to $50 million, reflecting its expected investment in development activities.

What are Esperion’s 2026 selling, general and administrative (SG&A) expense expectations?

The company expects 2026 SG&A expenses to be between $170 million and $195 million, covering commercial, corporate, and administrative costs.

What total operating expenses does Esperion project for 2026?

Esperion projects total operating expenses for 2026 in the range of $210 million to $245 million, which incorporates both R&D and SG&A spending.

Are Esperion’s 2026 guidance figures considered filed or furnished with the SEC?

The 2026 guidance included in the press release and presentation is described as furnished, not "filed," and is not subject to Section 18 liability of the Exchange Act, except where specifically incorporated by reference.